Related by context. All words. (Click for frequent words.) 69 cSSSI 68 daptomycin 67 ganetespib 66 BAY #-# 66 StaphVAX 65 tigecycline 65 nosocomial pneumonia 65 XmAb# 65 PRTX 65 anidulafungin 65 JAK inhibitor 64 Plicera 64 amrubicin 64 Amigal 64 Onrigin 64 obatoclax 64 dalbavancin 64 Telavancin 64 CD# monoclonal antibody 64 Restanza 64 Oritavancin 64 HuMax CD4 63 methylnaltrexone 63 posaconazole 63 MyVax R 63 oral prodrug 63 orally bioavailable 63 Tygacil 63 pomalidomide 63 lupus nephritis 63 NXL# 62 trabectedin 62 Sym# 62 Viramidine 62 proteasome inhibitor 62 Ceftobiprole 62 retapamulin 62 telavancin 62 otelixizumab 62 T Pred 62 IMA# 62 omacetaxine 62 cilengitide 62 DORIBAX 62 pralatrexate 62 axitinib 62 SCH # 62 delafloxacin 62 elotuzumab 62 fidaxomicin 62 ketolide antibiotic 62 phase IIb clinical 62 Symadex 62 iclaprim 62 micafungin 62 Phase Ib study 62 daclizumab 62 REP# 62 adecatumumab 62 Civacir 62 torezolid phosphate 62 CD# antibody [001] 62 investigational monoclonal antibody 62 docetaxel Taxotere R 62 HspE7 62 MGCD# [001] 62 CoFactor 61 Dalbavancin 61 #D#C# 61 OncoVEX 61 vosaroxin 61 ELACYT 61 pegylated 61 HuLuc# 61 PXD# 61 UPLYSO 61 Marqibo 61 pharmacokinetic properties 61 lomitapide 61 voreloxin 61 MyVax 61 receptor tyrosine kinase inhibitor 61 milatuzumab 61 Tyrima 61 radezolid 61 trastuzumab DM1 T DM1 61 Radezolid 61 OncoVEX GM CSF 61 Phase Ib 61 EndoTAG TM -1 61 virus HCV protease inhibitor 61 CYC# 61 forodesine 61 DXL# 61 Ceflatonin 61 histone deacetylase HDAC inhibitor 61 Noxafil 61 eltrombopag 61 ponatinib 61 Fodosine 61 investigational humanized monoclonal antibody 61 Cethromycin 61 PSN# [002] 61 vemurafenib 61 BAL# [001] 61 solithromycin 61 temsirolimus 61 Hycamtin 61 pegylated interferons 61 AEGR 61 carfilzomib 61 Anidulafungin 61 PRT# 61 Mycamine 61 polymerase inhibitors 61 CXA 61 palifosfamide 61 ceftazidime 61 PDE4 inhibitor 61 Xanafide 61 vilazodone 61 vinorelbine 61 ASONEP 61 sunitinib malate 61 Altastaph 61 PEGylated 61 Vibativ 61 Traficet EN 60 cyclophilin inhibitor 60 nucleoside analogues 60 anti leukemic 60 Nuvion 60 immunomodulatory 60 HQK 60 Cloretazine 60 bendamustine 60 YONDELIS 60 aflibercept 60 IMGN# 60 alvespimycin 60 Homspera 60 faropenem 60 Pruvel 60 ARIKACE 60 tolevamer 60 Ramoplanin 60 Icatibant 60 liposomal formulation 60 cancer immunotherapies 60 rilonacept 60 Alocrest 60 enzastaurin 60 TREANDA 60 Bezielle 60 reslizumab 60 liprotamase 60 anticancer compound 60 Amrubicin 60 ISTODAX 60 histone deacetylase inhibitor 60 mRCC 60 registrational 60 amphotericin B 60 favorable pharmacokinetic profile 60 Carfilzomib 60 OHR/AVR# 60 FOLOTYN ® 60 ridaforolimus 60 erlotinib Tarceva ® 60 TELINTRA 60 panitumumab 60 HCV protease 60 elvucitabine 60 FavId 60 adipiplon 60 sorafenib Nexavar 60 Aplidin 60 talactoferrin 60 decitabine 60 Nanobody ® 60 subcutaneous formulation 60 humanized anti 60 nanoviricide 60 TRIOLEX 60 Zalbin 60 AEG# 60 INCB# [001] 60 TYGACIL 60 ENMD # 60 pharmacokinetic studies 60 integrase inhibitor 60 ceftaroline 60 Cloretazine R 60 GLP toxicology studies 60 visilizumab 60 anticancer agent 60 Azixa 60 receptor inhibitor 60 PrevOnco 60 BiovaxID 60 Zavesca R 60 Hsp# inhibitors 60 Pralatrexate 60 Zolinza 60 JAK2 inhibitors 60 Alvesco R 60 Rezular 60 Telatinib 60 VIDAZA 60 Shigamabs ® 60 GALNS 60 iroxanadine 60 tanespimycin 60 RGB # 60 azacitidine 60 mapatumumab 60 pharmacokinetic interactions 60 huC# DM4 59 depsipeptide 59 Allovectin 7 ® 59 Seliciclib 59 vidofludimus 59 sapacitabine 59 HuMax EGFr 59 RDEA# 59 ITMN 59 midstage trials 59 telaprevir VX 59 subcutaneously administered 59 HGS# 59 L BLP# 59 Allovectin 7 R 59 anti EGFR antibody 59 nucleoside analog 59 superficial bladder cancer 59 Valortim 59 cethromycin 59 Omacetaxine 59 Phase IIb clinical trials 59 HGS ETR1 59 HCV protease inhibitor 59 Corlux 59 lintuzumab 59 TriRima 59 romidepsin 59 fluoroquinolone antibiotic 59 systemically administered 59 celgosivir 59 FluCide 59 maribavir 59 ganciclovir 59 hematological cancers 59 cangrelor 59 GAP #B# 59 tivozanib 59 TYZEKA 59 radiation sensitizer 59 Firazyr 59 MabCampath 59 Actemra tocilizumab 59 Phase 2a trial 59 Tarceva TM 59 Velcade bortezomib 59 imatinib Gleevec ® 59 Guanilib 59 Torisel 59 Phase Ib clinical 59 OMAPRO 59 doripenem 59 Factor VIIa 59 Fibrillex TM 59 vorinostat 59 CANCIDAS 59 Bortezomib 59 eniluracil 59 Golimumab 59 Clolar 59 velafermin 59 mycophenolate mofetil 59 TEMODAL 59 PDX pralatrexate 59 PD LID 59 bafetinib 59 Panzem R NCD 59 riociguat 59 meropenem 59 bovine thrombin 59 SinuNase 59 Junovan 59 biologic therapy 59 pharmacodynamic profile 59 Thiovir 59 cIAI 59 esophageal candidiasis 59 OPAXIO 59 ZADAXIN ® 59 HuMax CD# 59 injectable formulation 59 humanized monoclonal antibody 59 ongoing Phase 1b 59 Phenoptin 59 pegylated interferon alpha 59 veltuzumab 59 Targretin 59 immune modulatory 59 oral rivaroxaban 59 Neulasta ® 59 SCCHN 59 antiviral activity 59 oral antiviral 59 TACI Ig 59 MAGE A3 ASCI 59 linezolid 59 Aclidinium 59 phase IIa 59 TOCOSOL Paclitaxel 59 Advexin 59 Navelbine ® 59 registrational trial 59 VAPRISOL 59 Perifosine 59 Cloretazine ® 59 tocilizumab 59 nanoviricide drug 59 Vilazodone 59 ruxolitinib 59 pan HDAC inhibitor 59 midstage studies 59 tezampanel NGX# 59 Fludara 59 MEK inhibitor 59 small molecule defensin 59 nitazoxanide 59 Doribax 59 TKM ApoB 59 Laquinimod 59 vicriviroc 59 Dasatinib 59 anticancer therapy 59 VitiGam 59 HCV protease inhibitors 59 Dificid 59 thalidomide Thalomid 59 xenograft models 59 metastatic renal cell carcinoma 59 glufosfamide 58 valopicitabine 58 phase IIb 58 CCR5 antagonist 58 TPI ASM8 58 ARIKACE ™ 58 Vandetanib 58 Evoltra ® 58 Valortim R 58 Dacogen injection 58 Bicifadine 58 PLX cells 58 thymalfasin 58 Anthim 58 antitumor effect 58 caspofungin 58 liposomal amphotericin B 58 NNRTIs 58 Azedra 58 angiogenesis inhibitor 58 AP# [003] 58 imetelstat 58 NVA# 58 MEK inhibitors 58 teriflunomide 58 Annamycin 58 Daclizumab 58 T#I [002] 58 mertansine 58 ocrelizumab 58 OvaRex ® MAb 58 talabostat 58 Ceftaroline 58 Marketing Authorization Application MAA 58 Onco TCS 58 Gleevec imatinib mesylate 58 pharmacodynamic properties 58 PROCHYMAL 58 HGS ETR2 58 sorafenib tablets 58 CEQ# 58 tesetaxel 58 TRISENOX 58 seliciclib 58 interferon beta 1b 58 JAK inhibitors 58 HZT 58 heterozygous FH 58 nucleoside 58 Taxotere ® 58 Glybera 58 PROMACTA 58 histamine dihydrochloride 58 chemotherapy induced neutropenia 58 Cyclosporine 58 tafamidis 58 Onconase 58 denufosol 58 humanized antibodies 58 vancomycin 58 Maribavir 58 phase IIa clinical 58 rhThrombin 58 Panzem 58 tyrosine kinase inhibitor 58 dirucotide 58 plasma kallikrein inhibitor 58 OXi# 58 Nexavar sorafenib 58 atacicept 58 DU #b 58 metastatic RCC 58 antithrombotic 58 sargramostim 58 VEGF Trap 58 torezolid 58 Linjeta TM 58 Reverset 58 albinterferon alfa 2b 58 phase IIb trial 58 Mepact 58 VP# [004] 58 RSR# 58 NEUMUNE 58 Nexavar ® 58 Archexin 58 RSD# oral 58 cutaneous T cell 58 Abiraterone acetate 58 TOLAMBA 58 indolent NHL 58 IRX 2 58 belinostat 58 pegfilgrastim 58 rNAPc2 58 Arikace 58 Tolevamer 58 CR# vcMMAE 58 Zingo TM 58 dosing regimen 58 perifosine 58 SAR# [004] 58 Menerba 58 ISIS # 58 Aryplase 58 Shigamabs R 58 ofatumumab 58 Rhucin R 58 initiate Phase 1b 58 TMC# [001] 58 PCK# 58 chemotherapeutic drug 58 kinase inhibitor 58 NKTR 58 invasive candidiasis 58 HSP# inhibitor 58 BioVant 58 quinolone 58 preclinical studies 58 ACHN 58 macrolide 58 nucleoside analogs 58 Asentar 58 CDP# 58 BAL# [002] 58 ZYVOX 58 anti angiogenic agent 58 personalized immunotherapy 58 EOquin 58 investigational antiplatelet agent 58 inhaled formulation 58 Panzem R 58 interferon alfa 2b 58 multicenter Phase II 58 INCB# [002] 58 HepaGam B TM 58 lumiliximab 58 acyclovir Lauriad R 58 ONCONASE 58 DermaVir Patch 58 Phase 1b 58 viral kinetics 58 Aurora kinase 58 bosutinib 58 Folotyn 58 docetaxel Taxotere ® 58 Aflibercept 58 PI3K/Akt pathway inhibitor 58 vismodegib 58 ENMD 58 Nasdaq OPTR 58 tipifarnib 58 CHOP chemotherapy 58 alkylating agent 58 Gleevec resistant 58 sorafenib 58 MOZOBIL 58 Telaprevir 58 ceftobiprole 58 LE DT 58 lapatinib Tykerb 57 S/GSK# 57 Urocidin 57 LymphoStat B belimumab 57 LEUKINE 57 Acute Radiation Syndrome ARS 57 lenalidomide Revlimid R 57 Doxil ® 57 gefitinib Iressa 57 Proxinium TM 57 Rhucin 57 VFEND 57 NEBIDO 57 Cinryze 57 Phase IIB 57 renal toxicity 57 AKT inhibitor 57 nanoviricides 57 randomized Phase III 57 CIMZIA TM 57 PEG Interferon lambda 57 ATL# [001] 57 leukemia CLL 57 CBLC# 57 neratinib 57 Phase IIb trials 57 BEXXAR 57 cetuximab Erbitux R 57 docetaxel Taxotere 57 docetaxel chemotherapy 57 brivaracetam 57 Dyloject TM 57 AZILECT ® 57 pharmacokinetic PK 57 Vfend 57 Vectibix panitumumab 57 bevacizumab Avastin 57 cidofovir 57 dose escalation Phase 57 ESBA# 57 ixabepilone 57 pertuzumab 57 TELCYTA 57 Phase III clinical 57 panitumumab Vectibix 57 antibody MAb 57 BiTE antibody 57 Dapagliflozin 57 noninfectious uveitis 57 SEBIVO 57 TG# [003] 57 inhibitor RG# 57 Alzhemed TM 57 sunitinib 57 PS# [001] 57 trastuzumab Herceptin 57 immunomodulator 57 voriconazole 57 EGS# 57 Silodosin 57 methicillin resistant S. aureus 57 RhuDex ® 57 PSMA ADC 57 Plenaxis TM 57 Hyphanox 57 mTOR inhibitor 57 varespladib 57 FTY# 57 oral methylnaltrexone 57 ganaxolone 57 CYT# 57 MAA submission 57 tezampanel 57 teduglutide 57 immunotherapeutic 57 Cloretazine R VNP#M 57 diarrhea predominant irritable 57 lenalidomide dexamethasone 57 SARMs 57 JVRS 57 Cellegesic 57 CYT# QbG# 57 Nebido 57 Sorafenib 57 galiximab 57 VQD 57 Phase 1b trial 57 calcineurin inhibitors 57 Protectan CBLB# 57 Nanobody 57 Hedgehog Pathway Inhibitor 57 Arixtra 57 targeting CD# 57 candidemia 57 relapsed refractory multiple myeloma 57 refractory chronic lymphocytic 57 hereditary deficiency 57 RSD# 57 Altabax 57 epigenetic therapies 57 INGN 57 Vectibix 57 multi kinase inhibitor 57 Tavocept 57 injectable antibiotic 57 CINTREDEKIN BESUDOTOX 57 dyskinesia PD LID 57 BENLYSTA ® 57 Mycograb 57 nilotinib 57 intranasal delivery 57 ADVEXIN 57 MyVax ® 57 Phase Ib II 57 severe hypercholesterolemia 57 Marketing Authorization Application 57 Kamada AAT 57 Talabostat 57 oral ridaforolimus 57 iniparib 57 Clostridium difficile associated 57 triphendiol 57 Zysolin TM 57 antibody fragment 57 Personalized Immunotherapy 57 Denufosol 57 HAART regimens 57 refractory gout 57 CGEN # 57 invasive fungal infections 57 Tamibarotene 57 nonclinical studies 57 metastatic HRPC 57 dosing regimens 57 Phase 1b clinical 57 HoFH 57 PNP inhibitor 57 mAbs 57 lucinactant 57 ATryn R 57 vandetanib 57 PEG SN# 57 HDACi 57 dacetuzumab 57 PROVENGE sipuleucel T 57 multiple myeloma MM 57 immunomodulating 57 rituximab Rituxan 57 CCX# 57 Onalta ™ 57 G#DT 57 Increlex R 57 protein kinase inhibitor 57 Numax 57 HEPLISAV 57 oral salmon calcitonin 57 HepaGam B 57 ImmunoVEX HSV2 57 chronic HBV 57 balsalazide tablet 57 PMX # 57 relapsed SCLC 57 MT# MEDI 57 NOXAFIL 57 RezularTM 57 Aurexis 57 GSK# [001] 57 Zalypsis 57 bevirimat 57 ZYBRESTAT 57 Tesetaxel 57 phase 2a 57 microplasmin 57 tecarfarin 57 Phase 2b trial 57 ELND# 57 TORISEL 57 Alpharadin 57 thrombopoietin 57 placebo controlled Phase 57 Azilect ® 57 SERMs 57 alefacept 57 GTC recombinant human 57 platelet inhibitor 57 echinocandins 57 KNS # 57 clofarabine 57 LymphoStat B 57 evaluating tivozanib 57 intravenous dosing 57 dose cohort 57 ALN RSV# 57 Chemophase 57 Taxotere docetaxel 57 Cinryze ™ 57 Irinotecan 57 IAP inhibitor 57 ON #.Na 57 confirmatory Phase III 57 inhaled liposomal ciprofloxacin 57 NS#/#A protease 57 preclinical 57 MGd 57 Triolex 57 motavizumab 57 Aviptadil 57 REOLYSIN ® 57 pradefovir 57 pazopanib 57 erlotinib Tarceva 57 relapsing remitting multiple sclerosis 57 Genz # 57 azficel T 57 telithromycin 57 Clofarabine 57 Locteron 57 Stimuvax R 57 NP2 Enkephalin 57 VEGF receptor inhibitor 57 cannabinor 57 DACH platinum 57 atovaquone 57 SinuNase TM 57 Octreolin 57 elacytarabine 57 CRMD# 57 HCV antiviral 57 ALK inhibitor 57 bexarotene 57 RG# [001] 57 Cethrin 57 Nexavar tablets 57 LY# [003] 57 tyrosine kinase inhibitor TKI 57 cetuximab Erbitux ® 57 PrevOnco ™ 57 oral candidiasis 57 volociximab 57 investigational pan BCR 56 iloperidone 56 TMC# [002] 56 targeted antifolate 56 hypereosinophilic syndrome 56 HCD# [002] 56 octreotide acetate 56 MIRCERA 56 carcinogenicity study 56 macrolides 56 cSSSIs 56 interferon gamma 1b 56 Vorinostat 56 bortezomib Velcade 56 thorough QT 56 Mylotarg 56 anti CD# antibodies 56 fluoropyrimidine 56 hepatocellular carcinoma HCC 56 COPREXA 56 trodusquemine 56 MYCAMINE 56 Horizant 56 Unit Dose Budesonide 56 ocular formulation 56 PROSTVAC TM 56 romiplostim 56 voclosporin 56 imatinib mesylate 56 Anturol ® 56 Virulizin ® 56 IND enabling 56 NEUGENE 56 INTELENCE 56 novel peptide 56 Ceplene 56 Copegus ribavirin 56 MNTX 56 PI3K inhibitors 56 CIMZIA ™ 56 HCV SPRINT 56 miconazole Lauriad ® 56 Hsp# inhibitor 56 Phase IIa clinical trials 56 Complete Response 56 Mipomersen 56 piperacillin tazobactam 56 alfa interferon 56 maraviroc 56 ORENCIA ® 56 Zelrix 56 Clolar ® 56 APOPTONE 56 dasatinib Sprycel ® 56 picoplatin 56 preclinical efficacy 56 oral antifungal 56 ProSavin 56 compound PMX # 56 Revimmune 56 investigational compound 56 Veronate 56 DOS# 56 lesinurad 56 hoFH 56 Jevtana 56 eribulin mesylate 56 dose dose escalation 56 antifungal drugs 56 Linjeta ™ 56 Tekamlo 56 Increlex TM 56 CTAP# Capsules 56 HER2 positive metastatic breast 56 Phase IIIb clinical 56 ecallantide 56 peptide antigens 56 antibiotic resistant bacterial infections 56 NDA resubmission 56 generation cephalosporin antibiotic 56 oncolytic virus therapy 56 biodefense pathogens 56 taxanes 56 Firdapse 56 HCV infection 56 anticancer therapies 56 JANUVIA 56 rifamycin 56 MORAb 56 Insegia 56 Romiplostim 56 therapeutic monoclonal antibodies 56 tolerability profile 56 Gleevec imatinib 56 dasatinib 56 intravenous immunoglobulin 56 MAXY G# 56 AZILECT R 56 proteasome inhibitors 56 generation purine nucleoside 56 Valortim ® 56 boosted protease inhibitor 56 cell lymphoma CTCL 56 cutaneous T 56 synthetic retinoid 56 microtubule inhibitor 56 polymerase inhibitor 56 Evoltra 56 TRISENOX ® 56 DAVANAT 56 selective modulator 56 Ketotransdel 56 H#N# VLP vaccine 56 canakinumab 56 GRN#L 56 ATryn ® 56 SIR Spheres 56 DermaVir 56 #ME# 56 anticoagulant reversing agent 56 chemotherapeutics 56 vinca alkaloid 56 eculizumab 56 Myocet 56 AVP #D# 56 randomized Phase 56 preclinically 56 nab paclitaxel 56 DAS# [001] 56 mipomersen 56 Phase IIa clinical 56 Gram positive 56 BrachySil 56 FOLOTYN 56 VEGF inhibitor 56 Azedra ™ 56 Ambrisentan 56 Telintra 56 TBC# 56 Troxatyl 56 CDK inhibitor 56 OncoVex 56 BRIM2 56 Sebivo 56 Panitumumab 56 DOXIL 56 BLA submission 56 therapeutic monoclonal antibody 56 peginesatide 56 raltegravir 56 neuraminidase inhibitor 56 BCR ABL inhibitors 56 NEUGENE antisense 56 TRO# 56 HDAC inhibitor 56 Rhucin ® 56 Leukine 56 budesonide foam 56 zileuton 56 prucalopride 56 alvimopan 56 confirmatory clinical 56 phase Ib 56 injectable formulations 56 DIFICID 56 Satraplatin 56 Bendamustine 56 AzaSite Plus 56 Ophena TM 56 terlipressin 56 mifamurtide 56 AVN# [001] 56 Aurora kinase inhibitor 56 pivotal bioequivalence 56 Litx 56 YONDELIS R 56 ATL/TV# 56 R sorafenib tablets 56 immune modulators 56 onychomycosis 56 PLK1 SNALP 56 blinatumomab 56 ATPace TM 56 brostallicin 56 CytoFab 56 MAXY alpha 56 chronic HCV infection 56 gemifloxacin 56 zanolimumab 56 non nucleoside inhibitor 56 rFIXFc 56 Factor Xa inhibitor 56 huN# DM1 56 Taxotere R 56 Anturol 56 vinca alkaloids 56 PEP# [003] 56 DsiRNA 56 Tarvacin TM 56 IDX# 56 ambrisentan 56 investigational hepatitis C 56 pancreatic enzyme replacement 56 ACZ# 56 LUVENIQ 56 CA4P 56 active comparator 56 nalbuphine ER 56 interferon alfa 56 novel histone deacetylase 56 oxymorphone ER 56 cabazitaxel 56 AeroLEF TM 56 indacaterol 56 EFAPROXYN 56 Blinatumomab 56 regorafenib 56 selective inhibitor 56 ALGRX 56 L MTP PE 56 Epratuzumab 56 CUDC 56 PI3K inhibitor 56 LB# [003] 56 XEOMIN 56 entinostat 56 Onbrez Breezhaler 56 relapsed multiple myeloma 56 chlorambucil 56 antiplatelet agent 56 non metastatic osteosarcoma 56 HCV NS5B polymerase 56 ALN TTR# 56 anti angiogenic agents 56 cyclosporin 56 Certolizumab pegol 56 CCR9 antagonist 56 Octreotide 56 hepatitis C HCV 56 EOquin TM 56 Peginterferon alfa 2b 56 Vicinium TM 56 tremelimumab 56 Vidofludimus 56 Pemetrexed 56 Cintredekin Besudotox 56 imipenem 56 oral formulation 56 MYLOTARG 56 doxorubicin HCl liposome injection 56 Candida infections 56 vascular disrupting agent 56 ALTU 56 DAVANAT R 56 indibulin